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Abstract: The N-a-trimethyl 2-selenohistidine selenoneine is the 
selenium isolog of the natural antioxidant ergothioneine. Sulfur-to-
selenium substitutions are known to endow proteins and nucleic acids 
with special activities. In contrast, secondary metabolites that exploit 
selenium-specific chemistry are rare. Selenoneine therefore provides 
a unique opportunity to study how natural organoselenides interact 
with cellular processes. In this report we describe the chemical 
synthesis of selenoneine and other 2-selenoimidazoles. With 
synthetic selenoneine at hand we discovered a set of reactivities that 
distinguish selenoneine from ergothioneine, showing that the two 
compounds can fill distinct functional niches. Synthetic access to 2-
selenoimidazoles should pave the way to explore the pharmaceutical 
potential and physiological function of this heretofore inaccessible 
class of compounds.  
Selenium is a critical micronutrient for humans. Too little or too 
much of it can cause disease, including depression, dementia, 
immune deficiency, hair loss or cardiovascular disease.[1] 
Because selenium atoms have the same valency, 
electronegativity and almost the same size as sulfur atoms, many 
biosynthetic enzymes cannot efficiently distinguish between the 
two elements.[1b] As a result, most known selenium metabolites 
are isologs of the corresponding sulfur compounds including 
selenomethionine, selenocysteine, Se-adenosyl seleno-
methionine or selenobiotin.[1b, 2] Their cellular concentration is 
largely dependent on the selenium content in the environment and 
their physiological purpose is unclear.[3]  
In contrast, elaborate enzymatic machineries have evolved 
to enable targeted incorporation of selenium in the form of 
selenocysteine and 2-selenouridine into specific proteins and 
nucleic acids.[1b, 4] Specific sulfur-to-selenium substitutions can be 
advantageous because of the two elements show distinctly 
different reactivities.[1c] For example, selenols are more acidic and 
more reducing that thiols (pKa,SeH: ~ 5; pKa,SH: ~ 9).[5]  Selenols 
can efficiently react with triplet oxygen (3O2) whereas autoxidation 
of thiols usually depends on catalysis by transition metals.[6] 
Although diselenide bonds are more stable than disulfide bonds,[7] 
selenium generally forms 
 
Figure 1. a) Chemical structures of ebselen, selenoneine and ergothioneine. b) 
Synthesis of 2-imidazole diselenide 3. Reaction conditions: a) 1) Imidazole, NaI, 
K2CO3, DMF, 16 h; 2) Se, K2CO3, DMF, 80 °C, 16 h; 53 % yield; b) 1.7 M tBuLi 
in hexane; THF, -78 °C, 30 mins, 94 %. Synthesis of 8-11 were performed using 
similar procedures. Overall yields over three steps: 8: 41 %; 9: 42 %; 10: 55 %; 
11: 5 % 
weaker bonds with period 2 elements, allowing selenium 
compounds to engage more readily in making and breaking 
covalent bonds. Because of this versatility selenium has also 
been included in the design of artificial enzymes,[8] enzyme 
models,[9] protein ligation strategies, protein folding studies, [10] [7] 
or molecular probes.[11] Furthermore, the observation that ebselen 
(Figure 1a) and other synthetic organoselenides can catalyse 
peroxide reduction and form covalent bonds to specific proteins 
highlighted the therapeutic potential of such compounds.[11c, 12] 
Indeed, a number of recent studies indicate that ebselen may be 
used in the treatment of a wide range of health problems.[13] 
Surprisingly, there are very few examples of natural 
secondary metabolites that depends on selenium-specific 
chemistry for function. From such molecules one could learn how 
and where organoselenides – optimized by evolution – would 
interfere with cellular processes.[14] One of these rare examples is 
selenoneine (Figure 1a).[15] This selenium isolog of ergothioneine 
(Figure 1a) was first isolated from the muscle tissue of marine 
fish.[15-16] Selenoneine also accumulates in humans with a 
seafood-rich diet which raises questions about potential health 
risks or benefits emanating from this unusual selenium source.[16-
17] However, aside of intriguing indications that selenoneine may 
provide protection against mercury poisoning, [16, 18] little is known 
about the chemistry of such compounds.[19]  
In the quest of learning more, we developed the first chemical 
synthesis of unprotected 2-selenoimidazoles. Based on this  
 
 
[a] Dr. D. Lim and Prof. Dr. F.P. Seebeck*  
Department for Chemistry 
University of Basel 
Mattenstrasse 24a, 4002, Basel, Switzerland 
E-mail: florian.seebeck@unibas.ch 
[b] Prof. Dr. Dirk Gründemann  
Department of Pharmacology, University of Cologne, Faculty of 
Medicine and University Hospital Cologne, Gleueler Straße 24, 
50931, Cologne, Germany 
 Supporting information for this article is given via a link at the end of 
the document. 
COMMUNICATION          
 
 
 
 
 
Scheme 1. Total synthesis of selenoneine. Reaction conditions: a) 1) (Boc)2O, trimethylamine, MeOH; 2) K2CO3, MeOH, reflux, 2 h, 76 %; b) 1) phenylallyl bromide, 
K2CO3, NaI, DMF; 2) Se, K2CO3, 80 °C, 81 %; c) 1.7 M t-BuLi in hexane, THF, -78 °C, 30 mins, 100 %; d) 1) trifluoroacetic acid, triisopropylsilane, DCM; 2) CH2O, 
NaCNBH3, MeOH, 1 h, 53 % over two steps; e) 1) NaCNBH3, DCM, 30 mins; 2) triethylamine, ethylchloroformate, 10 °C, 1 h, 31 %; f) MeI, THF, 16 h, 21 %; g) 
LiOH.H2O, H2O, 1 h, 100 %. Synthesis protocols and characterization of compounds are described in the supporting information. 
 
 
methodology we synthesized selenoneine and characterized 
its properties in comparison with ergothioneine (Figure 1a). 
 
Presently, the only available selenoimidazole derivative 
is L-selenoneine that is isolated either from marine fish or from 
fermented Schizosaccharomyces pombe.[20] These sources 
are limited by low yields and restricted to the naturally 
occurring compound. Protocols to synthesize 2-
mercaptoimidazoles, including ergothioneine are well 
established,[21] but these procedures invariably fail in the 
synthesis of 2-selenoimidazoles. A suggested synthesis of 
selenoneine proved irreproducible in our hands and others.[20b, 
22] Approaches that were devised to make N-monosubstituted 
or N,N’-disubstituted 2-selenoimidazoles are comparatively 
inefficient [9, 23] and impose narrow restrictions on the range of 
permissible N-substituents.  
 
A key challenge in the synthesis of unprotected 2-
selenoimidazoles stems from the vulnerability of the carbon-
selenium (C-Se) bond towards harsh reductive and oxidative 
conditions. Hence, while alkylation of both nitrogen atoms is 
essential for attaching selenium to the imidazole ring,[23a] 
conditions for the subsequent deprotection are not compatible 
in the presence of the selone function. As a solution to this 
problem, we used 2-phenylallyl groups for N-protection.[24] As 
a first model synthesis imidazole was bis-alkylated with 
phenylallyl bromide 1 (Figure 1b). The resulting N,N-alkyl 
imidazolium was reacted with a weak base and elemental 
selenium to produce selone 2 in 53 % yield.  Treatment of 2 
with tert-butyl lithium allowed efficient removal of the 
phenylallyl groups to produce selenoimidazole which oxidized 
to the symmetric diselenide 3 (94 % yield). Similar procedures 
were used to synthesize the diselenides 8 - 11, including the 
isologs of lactoperoxidase and thyroid peroxidase (10),[23c, 23d, 
25] and known mercaptoimidazole-based inhibitors of 
lipoxygenase (11).[26]  
The synthesis of selenoneine was started with protection 
of the primary amine of L-histidine methyl ester 12 with tert-
butyloxycarbonyl to give 13 (Scheme 1).  Using the 
aforementioned phenylallyl protection, 13 was converted to 
selone 14. Deprotection of 14 gave the diselenide 15 in 
racemic form, as inferred by polarimetry. Removal of the Boc-
protecting group under acidic conditions, followed by reductive 
amination with formaldehyde gave dimethylamine 16 in 53 % 
yield over two steps. 16 was reduced and then reacted with 
ethyl chloroformate to give 17. Methylation with methyl iodide 
gave 18. Treatment of this compound with LiOH.H2O produced 
selenoneine, which was isolated as diselenide 19 in 2 % yield 
(120 mg) over 11 steps. 
In a next step we started to characterize the properties of 
synthetic selenoneine. As noted before selenoneine readily 
oxidizes to a stable diselenide.[27] In contrast, ergothioneine is 
largely resistant towards autooxidation and the symmetric 
disulfide slowly decomposes by hydrolysis at neutral pH.[28] 
The proton NMR spectra recorded of selenoneine and 
ergothioneine in buffered solutions at pH between 6 and 13 
show that both molecules are characterized by a single 
deprotonation event at alkaline pH (pKa,sel = 10.1, pKa,erg =  10.6, 
published pKa,erg = 10.8)[29], suggesting that both molecules are 
neutral under physiological conditions (Figure S1). This finding 
establishes that the higher propensity of selenoneine for 
oxidative dimerization is not due to higher acidity.  
 
The structural and electrostatic similarity of selenoneine 
and ergothioneine suggest that selenoneine could be an 
efficient substrate for the human ergothioneine transporter 
(ETTh).[30] To test this idea, the ETTh was expressed and 
assayed in human embryonic kidney 293 cells as established 
previously (Supporting information).[31] Briefly, adherent cells 
were incubated shortly with selenoneine at 37 °C in a 
chemically defined buffer. After washing and cell lysis, the 
selenoneine content was determined by Liquid 
Chromatography–Mass Spectrometry (LC-MS/MS). Uptake of 
selenoneine was saturable (Figure S2), with a KM of 27 (95% 
confidence interval, 16–46) μmol/L. Similar KM values were 
reported previously for ergothioneine and the ETT transporters 
from human (21 (16–28) µM),[30] pig (22 (12–39) μmol/L), and 
chicken (11 (8–17) μmol/L).[32] In the particular experiment 
shown, with a Vmax of 560 (standard error, ± 32) pmol min-1 mg 
protein-1, the clearance (Vmax/KM, a measure of transport 
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efficiency) was 21 µL min-1 mg protein-1, somewhat lower than 
typically measured (i.e. 50-100 µL min-1 mg protein-1) for 
ergothioneine and ETTh in our expression system. 
Nevertheless these data support the idea that selenoneine is 
efficiently distributed in the human body even at low 
concentrations.[17a, 19] 
An earlier study examined selenoneine uptake using the 
diselenide form, and quantified uptake indirectly by Inductively 
Coupled Plasma Mass Spectrometry (ICP-MS), using total 
selenium content as a proxy.[17a] This experiment raised the 
possibility that the diselenide instead of or in addition to the 
reduced form might be a substrate for the ETTh. To test this 
possibility, we prepared a redox-stable analogue of 
selenoneine diselenide by linking two selones with a single 
methylene group (20, Scheme 1). Accumulation of this 
compound (incubation time 1 min, 1 µM and 10 µM) in ETT-
expressing cells was not higher than in control cells (not 
shown). By contrast, uptake of ergothioneine (1 min, 10 µM) 
measured in paired dishes was 30-fold higher in ETT-
expressing cells than in control cells. Thus, we conclude that 
ETTh cannot efficiently transport 20. This finding underscores 
the strict substrate specificity of ETTh and establishes that 
selenoneine is transported in reduced form.[31]  Most likely, the 
complex cell culture medium used in the previous uptake 
experiments contained sufficient free thiols (> 30 µM) to reduce 
all or a fraction of the diselenide. Similarly, the extracellular 
plasma contains a considerable pool of free thiols (~0.4–0.6 
mM, mostly Cys34 on human serum albumin) that may account 
for the efficient uptake of selenoneine in the human body.[33]  
 
Scheme 2. Reactions of ergothioneine (a) and selenoneine (b) with H2O2 
 
 
A final set of experiments were designed to compare the 
redox reactivity of selenoneine and ergothioneine. The 
consensus opinion in the literature posits that ergothioneine 
protects cells from oxidative stress.[34] One way to decipher the 
mechanisms of ergothioneine-based cytoprotection is to  study 
the redox reactivity of ergothioneine and its oxidation 
products.[28a, 35] Treatment with reactive oxygen species such 
as hydrogen peroxide and superoxide was shown to convert 
ergothioneine to TMH (21, Scheme 2, Figure S3) or 
ergothioneine sulfonic acid (22). Both metabolites have been 
isolated from biological samples, indicating that oxidative 
degradation of ergothioneine is a physiologically relevant 
process.[34d] The intermediate oxidation products ergothioneine 
disulphide (23) and ergothioneine sulfinic acid (24) are less 
stable and do not accumulate.[28a] Selenoneine shows a very 
different behaviour. Conditions that completely desulfurize 
ergothioneine, convert selenoneine to the stable seleninic acid 
(25, Figure S4). The same product emerges from a reaction of 
hydrogen peroxide with selenoneine diselenide, suggesting 
that the diselenide is an intermediate in the formation of 
seleninic acid. Deselenation of the seleninic acid was observed 
as a slow and hydrogen peroxide dependent reaction (rate: [3 
± 1] x 10-3 min-1), suggesting that further oxidation to the 
unstable selenonic acid (26) is a prerequisite for C-Se bond 
cleavage.  
On the other hand, 25 reacts rapidly and quantitatively 
with GSH or DTT to reform selenoneine (Figure S4).[36] This 
reactivity suggest that in a cellular context reductive recycling 
of 25 is much more efficient than deselenation. Consequently, 
selenoneine is more resistant towards irreversible oxidative 
degradation than ergothioneine. Indeed, resistance towards 
oxidative deselenation has been suggested as the main 
evolutionary incentive for replacement of specific sulfur atoms 
with selenium in proteins, nucleic acids and - as exemplified by 
selenoneine - in secondary metabolites.[37] 
 
Under aerobic conditions and in the absence of reducing 
equivalents the most stable form of selenoneine is the 
diselenide 19.[16, 20b] Based on the report that selenenyl sulfides 
and seleninic acids react with electron-rich arenes via 
electrophilic aromatic substitution,[38] we wondered as to 
whether selenoneine diselenide would react in a similar way. 
Indeed, incubation of selenoneine diselenide with resorcinol in 
a buffered aqueous solution at 37 °C for 24 h readily produced 
a selenoneine adduct of resorcinol (27, Figure S5). Although 
resorcinol is not itself a known natural product, 1,3-
benzenediol motifs are common among phenylpropanoids, 
terpenoids, polyketides and nonribosomal peptides. Therefore, 
it is possible that a broad range of selenoneine adducts of 
natural products may have yet to be discovered from natural 
sources. To provide a few explicit examples  we reacted the 
phenylpropanoid resveratrol, the nonribosomal peptide 
vancomycin and polyketide proansamitocin[39]  with 
selenoneine diselenide to produce the corresponding adducts 
(28 - 30, Figure 2).  
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Figure 2. Reactivity of selenoneine diselenide with C-nucleophiles. Reaction conditions: Selenoneine diselenide (0.2-1 mM), arene (4-10 mM), 0.1 M Tris (pH 8), 
H2O or H2O/EtOH (9:1), 37 °C, 24 h. Products were identified by HR-ESI-MS. Yields were determined by HPLC peak integration (27: 89 %; 28: 86 %; 29: 87 %; 30: 
5 %). 
 
Conclusions. In this report we describe a general method for 
the synthesis of N-alkylated and unalkylated 2-
selenoimidazoles. We demonstrated that synthetic 
selenoneine is imported by human cells with similar efficiency 
as ergothioneine. Selenoneine was shown to engage in 
reversible oxidation and reduction reaction under conditions 
that irreversibly degrade ergothioneine. These findings 
suggest that selenoneine is a more robust antioxidant than 
ergothioneine. Selenoneine diselenide was shown to react with 
complex natural products via electrophilic aromatic substitution 
to form selenoneine adducts. These reactions occur under 
physiological conditions raising the possibility that adduct 
formation may be part of selenoneines functional portfolio. The 
different reactivities of selenoneine and ergothioneine support 
the idea that the two compounds fill distinct functional niches 
in biology.    
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